AstraZeneca is global innovation-driven biopharmaceutical company specialising in the discovery, development, manufacturing and marketing of prescription medicines that make a meaningful difference in healthcare. AstraZeneca discovers new medicines that are designed to improve the health and quality of life of patients around the world - medicines which are innovative, effective and which offer added benefits such as reduced side effects or better ways of taking the treatment. They also focus on getting the best from every medicine they make by exploring all the ways it can be used or improved. Their business strategy sets out their path to success in delivering great medicines to patients through innovative science and global excellence in development and commercialisation.
Cambridge, GB
Size (employees)
59,700 (est)
AstraZeneca was founded in 1999 and is headquartered in Cambridge, GB
Report incorrect company information

Key People/Management at AstraZeneca

Pascal Soriot

Pascal Soriot

Executive Director and Chief Executive Officer
Marcus Wallenberg

Marcus Wallenberg

Non-Executive Director
Nazneen Rahman

Nazneen Rahman

Non-Executive Director
Baroness Vadera

Baroness Vadera

Non-Executive Director
Geneviève Berger

Geneviève Berger

Non-Executive Director
Philip Broadley

Philip Broadley

Non-Executive Director
Graham Chipchase

Graham Chipchase

Non-Executive Director
Deborah DiSanzo

Deborah DiSanzo

Non-Executive Director
Sheri McCoy

Sheri McCoy

Non-Executive Director
Rudy Markham

Rudy Markham

Senior Independent Non-Executive Director
Leif Johansson

Leif Johansson

Non-Executive Chairman of the Board

AstraZeneca Office Locations

AstraZeneca has an office in Seattle, New Haven, Tampa, Jersey and in 166 other locations
Shanghai, CN
43/F CITIC Square, 1168 Nan Jing Xi Road
Wedel, DE
Wedel, Tinsdaler Weg 183
Hong Kong, HK
18/F, Shui On Centre, 6-8 Harbour Road, Wanchai
Bangalore, IN
Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road
Osaka, JP
Grand Front Osaka Tower B, 3-1, Ofuka-cho, Kita-ku
London, GB
15 Stanhope Gate
Show all (171)
Report incorrect company information

AstraZeneca Financials and Metrics

AstraZeneca Financials

AstraZeneca's revenue was reported to be $21.32 b in FY, 2016 which is a 9.8% decrease from the previous period.

Revenue (FY, 2016)

21.3 b

Revenue growth (FY, 2015 - FY, 2016), %


Gross profit (FY, 2016)

17.2 b

Gross profit margin (FY, 2016), %


Net income (FY, 2016)

3.4 b

Market capitalization (2-Oct-2017)

87.4 b

Closing share price (2-Oct-2017)


Cash (4-Mar-2018)

3.9 b
AstraZeneca's current market capitalization is $87.4 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016


25.7 b26.1 b23.6 b21.3 b

Revenue growth, %


Cost of goods sold

5.3 b5.8 b4.6 b4.1 b

Gross profit

20.5 b20.3 b19 b17.2 b
GBPFY, 2013FY, 2014FY, 2015FY, 2016


6.1 b4.7 b4.6 b3.9 b

Accounts Receivable

3.6 b3.5 b3.4 b2 b

Current Assets

13.2 b12.2 b11.7 b10.1 b


6.4 b7 b7.2 b8 b
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash From Operating Activities

7.4 b7.1 b3.3 b4.1 b

Cash From Financing Activities

(2 b)(2 b)649.3 m1.7 b

Income Taxes Paid

(457.7 m)(8.1 m)(179.7 m)(113.1 m)
USDY, 2016

Financial Leverage

4.2 x
Show all financial metrics

AstraZeneca Operating Metrics

FY, 2013FY, 2014FY, 2015FY, 2016

Healthcare Workers

2.60 k3 k


100 100 100 100

Drugs Approved by FDA


Health Facilities Activated

250 403
Show all operating metrics
Report incorrect company information

AstraZeneca News and Updates

AstraZeneca owes $192M in royalties from massive Merck deal, selumetinib licensor Array argues

AstraZeneca and Merck made waves last year with an immuno-oncology tie-up worth up to $8.5 billion, with $1.6 billion up front. But Array BioPharma, an AstraZeneca partner since 2003, says the London drug giant has refused to pay royalties on selumetinib, a drug it invented and licensed to AZ and on…

ACC: Waiting on the FDA's heart-helping verdict, J&J shares more positive CV data for Invokana

ORLANDO—Johnson & Johnson is waiting for word from the FDA on whether it’ll become the second diabetes drug in its class to snag an approval for cardiovascular risk reduction. But in the meantime, it’s trumpeting more outcomes data to support its case.

ACC: AstraZeneca unveils more SGLT2 heart benefits with latest batch of real-world data

When it comes to real-world heart benefits, SGLT2 diabetes drugs continue to impress. In a study of more than 400,000 Type 2 diabetes patients, researchers drew an association between treatment with SGLT-2s—including AZ’s own Farxiga, J&J’s Invokana and Boehringer Ingelheim and Eli Lilly’s Jardi…

Performance Enhancing Drugs Market 2018 – Top Players | Industry Analysis | CAGR 4.8% by 2023

Performance Enhancing Drugs Market includes 90 pages, Full TOC, List of Tables, List of Figures and many of the features such as Report Prologue, Market Introduction, Research Methodology, Market Dynamics, Market Factor Analysis, and Global Performance Enhancing Drugs Market by (type, Products, End …

Lilly, Boehringer add two Jardiance heart failure studies to examine effects on exercise

Eli Lilly and Boehringer Ingelheim are gunning for a heart-failure nod for diabetes drug Jardiance. And if they can get it, they want to be able to talk up the product’s effects on exercise ability, too.

AstraZeneca petitions for longer construction hours at long-delayed HQ

AstraZeneca’s in-the-works Cambridge, U.K., headquarters is already behind schedule, and now, construction may drag on through the middle of next year.
Show more
Report incorrect company information